U.S. Markets open in 1 hr 52 mins
  • S&P Futures

    3,816.75
    -8.75 (-0.23%)
     
  • Dow Futures

    30,906.00
    -27.00 (-0.09%)
     
  • Nasdaq Futures

    11,637.50
    -36.75 (-0.31%)
     
  • Russell 2000 Futures

    1,734.10
    -4.20 (-0.24%)
     
  • Crude Oil

    112.77
    +1.01 (+0.90%)
     
  • Gold

    1,828.10
    +6.90 (+0.38%)
     
  • Silver

    20.95
    +0.08 (+0.40%)
     
  • EUR/USD

    1.0527
    +0.0002 (+0.0211%)
     
  • 10-Yr Bond

    3.2060
    0.0000 (0.00%)
     
  • Vix

    28.94
    +1.99 (+7.38%)
     
  • GBP/USD

    1.2170
    -0.0015 (-0.1205%)
     
  • USD/JPY

    136.4290
    +0.3010 (+0.2211%)
     
  • BTC-USD

    20,066.20
    -972.95 (-4.62%)
     
  • CMC Crypto 200

    432.62
    -17.44 (-3.88%)
     
  • FTSE 100

    7,285.01
    -38.40 (-0.52%)
     
  • Nikkei 225

    26,804.60
    -244.87 (-0.91%)
     

9 Meters Biopharma to Present at the Maxim Group 2022 Virtual Growth Conference

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

RALEIGH, NC / ACCESSWIRE / March 21, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that John Temperato, President & Chief Executive Officer of 9 Meters, will present at the Maxim Group 2022 Virtual Growth Conference hosted by M-Vest on March 28 - 30, 2022.

Maxim Group 2022 Virtual Growth Conference

Presentation: Available for viewing on March 28 - 30, 2022

Webcast: https://m-vest.com/events/2022-virtual-growth-conference/p/nmtr

The presentation will also be available in the events section of the 9 Meters website.

The presentation will highlight the Company's advanced pipeline and upcoming clinical milestones for vurolenatide, its long-acting GLP-1 agonist for short bowel syndrome, currently in a Phase 2 clinical study with data anticipated in the second quarter of 2022, and larazotide, its Phase 3 tight junction regulator for celiac disease, with an interim analysis anticipated in early June 2022.

About 9 Meters Biopharma

9 Meters Biopharma, Inc. is a clinical-stage company pioneering novel treatments for people with rare digestive diseases, GI conditions with unmet needs, and debilitating disorders in which the biology of the gut is a contributing factor. The Company is advancing vurolenatide, a proprietary Phase 2 long-acting GLP-1 agonist, for short bowel syndrome (SBS); larazotide, a Phase 3 tight junction regulator in non-responsive celiac disease; and several near clinical-stage assets.

For more information please visit www.9meters.com or follow 9 Meters on Twitter and LinkedIn.

Forward-Looking Statements

This press release includes forward-looking statements based upon the Company's current expectations. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, anticipated milestones and any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation: reliance on research and development partners; uncertainties associated with the clinical development and regulatory approval of product candidates; uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; risks related to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; the impact of COVID-19 on our operations, enrollment in and timing of clinical trials; intellectual property risks; risks related to the inability of the Company to obtain sufficient additional capital to continue to advance these product candidates and its preclinical programs; reliance on collaborators; and risks associated with acquiring and developing additional compounds. These and other risks and uncertainties are more fully described in periodic filings with the SEC, including the factors described in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2020, Form 10-Q for the quarter ended September 30, 2021, and in other filings that the Company has made and future filings the Company will make with the SEC. You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof or as of the dates indicated in the forward-looking statements. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Corporate Contact

Al Medwar
SVP, Investor Relations & Corporate Communications
9 Meters Biopharma, Inc.
investor-relations@9meters.com

Media Contact
Veronica Eames
LifeSci Communications, LLC
veames@lifescicomms.com
203-942-4626

SOURCE: 9 Meters Biopharma, Inc.



View source version on accesswire.com:
https://www.accesswire.com/693798/9-Meters-Biopharma-to-Present-at-the-Maxim-Group-2022-Virtual-Growth-Conference